IP Library › Granted Patent US 12,336,979
Granted Patent B2
US 12,336,979 · App. 17/546,204 · Granted Jun 24, 2025

Material and method for treating cancer

Inventors: Yulia Hionidi (Petah Tiqwa, IL); Omer Tsipori (Sha'ar Efraim, IL); Marina Konorty (Hertzeliya, IL)
Assignee: UroGen Pharma Ltd.
A61K31/407A61K9/06A61K47/10A61K47/18A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,336,979
App. No.
17/546,204
Granted
Jun 24, 2025
Kind
B2
Abstract

A kit provides for sustained release of therapeutic agents for local treatment of cancer diseases by providing lyophilized Mitomycin C in a slowly releasing biocompatible hydrogel to be applied to affected tissue. The hydrogel comprises poloxamer 407, hydroxypropylmethylcellulose and water. A lyophilized composition comprises mitomycin C and urea as a bulking agent.

Claims (12)

1. A kit comprising:

(a) a biocompatible thermoreversible hydrogel comprising

from 15% to 35% (w/w) of Poloxamer 407 based on a total weight of the biocompatible thermoreversible hydrogel,

from 0.01% to 0.3% (w/w) of hydroxypropylmethylcellulose based on a total weight of the biocompatible thermoreversible hydrogel, and

water; and

(b) a lyophilized composition comprising mitomycin C and a bulking agent,

wherein the bulking agent is urea.

2. The kit according to claim 1 , wherein the biocompatible thermoreversible hydrogel further comprises from 0.1% to 1.8% (w/w) of PEG-400 based on a total weight of the biocompatible thermoreversible hydrogel.

3. The kit according to claim 2 , wherein mitomycin C and the bulking agent are present in a ratio of about 1:8 in the lyophilized composition.

4. The kit according to claim 2 , wherein mitomycin C and the bulking agent are present in a ratio of about 1:7 to about 1:14 in the lyophilized composition.

5. The kit according to claim 1 , wherein mitomycin C and the bulking agent are present in a ratio of about 1:8 in the lyophilized composition.

6. The kit according to claim 1 , wherein mitomycin C and the bulking agent are present in a ratio of about 1:7 to about 1:14 in the lyophilized composition.

Assignments (8)
SECOND AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Mar 2, 2026
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 074994/0338 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Aug 18, 2025
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 072472/0233 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Mar 6, 2025
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC [COLLATERAL AGENT]
Reel/Frame 070434/0319 →
PATENT SECURITY AGREEMENT Recorded Mar 18, 2024
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC
Reel/Frame 066805/0346 →
PATENT SECURITY AGREEMENT Recorded Aug 18, 2023
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC
Reel/Frame 064641/0263 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded May 19, 2022
From: UROGEN PHARMA LTD.
To: RTW INVESTMENTS ICA V
Reel/Frame 060121/0591 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2022
From: HIONIDI, YULIA; TSIPORI, OMER; KONORTY, MARINA
To: UROGEN PHARMA LTD.
Reel/Frame 059528/0317 →
SECURITY INTEREST Recorded Mar 18, 2022
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC
Reel/Frame 059302/0501 →
Continuity (2)
Provisional Application 63124111 · Dec 11, 2020
Related Publication 20220202773A1 · Jun 30, 2022
References Cited (46)
US 6286513B1 · Au et al. · 2001 [cited by applicant]
US 6482435B1 · Stratton et al. · 2002 [cited by applicant]
US 7723085B2 · Smith et al. · 2010 [cited by applicant]
US 9040074B2 · Holzer · 2015 [cited by examiner]
US 9801854B1 · Strauss-Ayali · 2017 [cited by examiner]
US 9950069B2 · Holzer · 2018 [cited by examiner]
US 10039832B2 · Holzer · 2018 [cited by examiner]
US 10471150B2 · Konorty et al. · 2019 [cited by applicant]
US 20040009212A1 · Tsai · 2004 [cited by applicant]
US 20070275110A1 · Dott et al. · 2007 [cited by applicant]
US 20090142259A1 · Gao et al. · 2009 [cited by applicant]
US 20090214685A1 · Hunt · 2009 [cited by applicant]
US 20100015200A1 · McClain et al. · 2010 [cited by applicant]
US 20130046275A1 · Holzer et al. · 2013 [cited by applicant]
US 20140105884A1 · Konorty et al. · 2014 [cited by applicant]
US 20140142191A1 · De La Zerda et al. · 2014 [cited by applicant]
US 20150366974A1 · Holzer et al. · 2015 [cited by applicant]
US 20160256391A1 · Schuldt-Lieb · 2016 [cited by examiner]
US 20170112935A1 · Holzer et al. · 2017 [cited by applicant]
US 20170128424A1 · Rothstein · 2017 [cited by applicant]
US 20170136127A1 · Maki et al. · 2017 [cited by applicant]
US 20170143833A1 · De La Zerda et al. · 2017 [cited by applicant]
US 20190201334A1 · Hakim · 2019 [cited by examiner]
US 20200114008A1 · Konorty · 2020 [cited by applicant]
US 20220118096A1 · Konorty · 2022 [cited by applicant]
US 20230233685A1 · Holzer et al. · 2023 [cited by applicant]
US 20230241220A1 · Holzer et al. · 2023 [cited by applicant]
US 20230241221A1 · Holzer et al. · 2023 [cited by applicant]
EP 0386960A2 · 1990 [cited by applicant]
WO WO2011089604A2 · 2011 [cited by applicant]
WO WO2013011504A1 · 2013 [cited by applicant]
WO 2018169960A1 · 2018 [cited by applicant]
WO WO2022123480A1 · 2022 [cited by applicant]
Calderon, C. P.; Daniels, A. L.; Randolph, T. W. “Deep Convolutional Neural Network Analysis of Flow Imaging Microscopy Data to Classify Subvisible Particles in Protein Formulations” Journal of Pharmaceutical Sciences 1… [cited by examiner]
Rey-Rico, A.; Cucchiarini, M. “PEO-PPO-PEO Tri-Block Copolymers for Gene Delivery Applications in Human Regenerative Medicine—An Overview” Int. J. Mol. Sci. 19, 775; doi:10.3390/ijms 19030775, 2018. (Year: 2018). [cited by examiner]
International Search Report for International Patent Application No. PCT/IB2021/061499, mailed on Feb. 23, 2022. [cited by applicant]
Written Opinion of the International Searching Authority for International Patent Application No. PCT/IB2021/061499, mailed on Feb. 23, 2022. [cited by applicant]
H.T. Ta, et al., “Injectable chitosan hydrogels for localised cancer therapy”, Journal of Controlled Release, vol. 126, pp. 205-216 (2008). [cited by applicant]
Y. You, et al., “Intraoperative Mitomycin C in Dacryocystorhinostomy”, Opthalmic Plastic and Reconstructive Surgery, vol. 17, No. 2, pp. 115-119 (2001). [cited by applicant]
H. Wang, U.S. Pharmacopeia, http://www.pharmacopeia.cn/v29240/usp29nf24s0_m66210.html, vol. 29, No. 6, p. 2020 (2007), retrieved from the internet on Feb. 21, 2024. [cited by applicant]
X. Gao, et al., “Bladder Tissue Uptake of Mitomycin C during Intravesical Therapy is Linear with Drug Concentration in Urine”, Clinical Cancer Research, vol. 3, pp. 139-143 (1998). [cited by applicant]
T.D. Schmittgen, et al., “Pharmacodynamics of Mitomycin C in Cultured Human Bladder Tumors”, Cancer Research, vol. 51, pp. 3849-3856 (1991). [cited by applicant]
Technical Bulletin, Pluronic Block Copolymer NF Grades (Poloxamer NF Grades), BASF The Chemical Company, 2 pages (2002). [cited by applicant]
S. Miyazaki, et al., “Antitumor Effect of Pluronic F-127 Gel Containing Mitomycin C on Sarcoma-180 Ascites Tumor in Mice”, Chem. Pharm. Bull. 40(8) 2224-2226 (1992). [cited by applicant]
E. Bilensoy, et al., “Mucoadhesive, Thermosensitive, Prolonged-Release Vaginal Gel for Clotrimazole: beta-Cyclodextrin Complex”, AAPS PharmSciTech 2006; 7(2) Article 38 (http://www.aapspharmscitech.org). [cited by applicant]
JELMYTO (mitomycin) [package insert]. Princeton, NJ: UroGen Pharma, Inc; Apr. 2020. [cited by applicant]